Securities code: 002758 securities abbreviation: Zjamp Group Co.Ltd(002758) Announcement No.: 2021-072
Bond Code: 128040 bond abbreviation: Huatong convertible bond
As for the closing of some raised investment projects of the company, the surplus raised funds will be permanently replenished
Announcement on the change of funds and the use of some raised funds
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
Zjamp Group Co.Ltd(002758) (hereinafter referred to as “the company” or ” Zjamp Group Co.Ltd(002758) “) held the 18th meeting of the 4th board of directors on December 23, 2021, deliberated and adopted the proposal on closing some of the company’s raised investment projects, permanently replenishing the surplus raised funds and changing the use of some raised funds, and agreed that the company would The fund-raising and investment project of “pharmaceutical wholesale business expansion project” shall be closed, and the surplus fund-raising shall be permanently supplemented with working capital. At the same time, the purpose of the fund-raising of “chain drugstore expansion project” shall be changed for the company’s “digital system upgrading and construction project”. This proposal still needs to be considered by the general meeting of shareholders of the company. The relevant information is announced as follows:
1、 Use of funds raised by initial public offering
(i) Basic information of raised funds
Approved by the reply on Approving the initial public offering of shares of Zhejiang Huatong Pharmaceutical Co., Ltd. (zjxk [2015] No. 838) of China Securities Regulatory Commission and approved by Shenzhen Stock Exchange, the company issued RMB common shares for the first time (A shares) 14 million shares, with an issue price of 18.04 yuan per share. The total amount of funds raised in this issue is 252.56 million yuan. After deducting the expenses related to the issue of 31.5832 million yuan, the net amount of funds raised is 220.9768 million yuan. All the above funds were in place on may 22, 2015 and have been verified by Lixin Accounting firm (special general partnership) and issued a letter of certified public accountant [2015] No. 610388 capital verification report. The funds raised by the company are used for the three projects of “pharmaceutical logistics phase II construction project”, “chain drugstore expansion project” and “pharmaceutical wholesale business expansion project”, and the raised funds are stored in a special account.
The investment projects and use plans of the funds raised from the initial public offering disclosed in the prospectus for initial public offering of shares of the company are as follows:
Unit: 10000 yuan
No. total investment amount of raised funds project investment amount of raised funds to be used
1 pharmaceutical logistics phase II construction project 12024.5212024.52
2 chain drugstore expansion project 6902.476073.16
3 pharmaceutical wholesale business expansion project 6732.094000.00
Total 25659.0822097.68
As of November 30, 2021, the balance of the special account for raised funds is as follows:
Unit: 10000 yuan
Deposit bank account name bank account number account nature closing balance
Agricultural Bank Of China Limited(601288) Zhejiang Agricultural Group Co., Ltd. 19510401040007596 current deposit account 1014.04 company
Agricultural Bank Of China Limited(601288) Zhejiang Huayao Logistics Co., Ltd. 19510401040007885 current deposit account 11.62 company
Zhejiang Shaoxing Ruifeng Rural Commercial Bank Co.Ltd(601528) Zhejiang Agricultural Group Co., Ltd. 201000137948137 current deposit account 3.49 company
China Citic Bank Corporation Limited(601998) Zhejiang Agricultural Group Co., Ltd. 8110801013800000926 current deposit account 3363.78 company
China Citic Bank Corporation Limited(601998) Zhejiang Huatong pharmaceutical chain 811080101430074790 current deposit account 1660.80 Co., Ltd
Total 6053.73
（2） Previous changes and extensions of the company’s raised investment projects
1. Changes in investment projects of some raised funds in 2016
On September 13, 2016, the second extraordinary general meeting of shareholders of the company in 2016 deliberated and approved the proposal on changing some matters related to the investment projects with raised funds, and agreed to change the relevant matters of “chain drugstore expansion project” and “pharmaceutical logistics phase II construction project”. As of June 30, 2016, the accumulated used raised funds of the company are as follows:
Unit: 10000 yuan
S / n project name: cumulative investment progress of raised funds to be used (%)
Investment amount
1 pharmaceutical logistics phase II construction project 12024.524771.4839 sixty-eight
2. Chain drugstore expansion project 6073.16770 nine thousand five hundred and twelve point six nine
S / n project name: cumulative investment progress of raised funds to be used (%) investment amount
3. Pharmaceutical wholesale business expansion project 4000.003998.1799 ninety-five
2. Investment projects of deferred part of raised funds in 2019
On May 13, 2019, the company’s 2018 annual general meeting of shareholders deliberated and approved the proposal on the extension of some raised investment projects, and agreed that the company’s “chain drugstore expansion project” should be postponed until March 31, 2020. As of December 31, 2018, the accumulated used raised funds of the company are as follows:
Unit: 10000 yuan
No. project name proposed to use raised funds to invest and raise funds cumulative investment progress (%) amount
1 pharmaceutical logistics phase II construction project 12024.5210691.4488 ninety-one
2. Chain drugstore expansion project 6073.161248.6920 fifty-six
3. Pharmaceutical wholesale business expansion project 4000.003998.1799 ninety-five
3. Investment projects of some raised funds postponed in 2020
On May 8, 2020, the 2019 annual general meeting of shareholders of the company deliberated and approved the proposal on the extension of some raised investment projects, and agreed that the company’s “chain drugstore expansion project” should be postponed until September 30, 2021. As of December 31, 2019, the accumulated used raised funds of the company are as follows:
Unit: 10000 yuan
No. project name proposed to use raised funds to invest and raise funds cumulative investment progress (%) amount
1 pharmaceutical logistics phase II construction project 12024.5211523.4295 eighty-three
2. Chain drugstore expansion project 6073.161511.7924 eighty-nine
3. Pharmaceutical wholesale business expansion project 4000.003998.1799 ninety-five
4. As of November 30, 2021, the use of raised funds
As of November 30, 2021, the accumulated used raised funds of the company are as follows:
Unit: 10000 yuan
No. project name proposed to use raised funds to invest and raise funds cumulative investment progress (%) amount
1 pharmaceutical logistics phase II construction project 12024.5211636.4196 seventy-seven
2. Chain drugstore expansion project 6073.161660.7627 thirty-five
3. Pharmaceutical wholesale business expansion project 4000.003998.1799 ninety-five
2、 Summary of closing of some raised investment projects and permanently supplementing the surplus raised funds with working capital
(i) Reasons for closing and surplus funds of some raised investment projects
The investment projects of the raised funds to be settled this time are “pharmaceutical logistics phase II construction project” and “pharmaceutical wholesale business expansion project”. The above projects have completed the implementation progress and reached the expected usable state. The specific completion of the project is as follows:
1. Pharmaceutical logistics phase II construction project
As of November 30, 2021, the “phase II construction project of pharmaceutical logistics” has been implemented, and the project has reached the expected usable state. The accumulated use of raised funds is 116.3641 million yuan, and the progress of fund use is 96.77%. At the same time, the special account of raised funds has generated certain interest income during the storage period. Specific fund use and savings are as follows:
Unit: 10000 yuan
Project Name: it is proposed to use the raised funds, the accumulated investment interest income of the raised funds and the remaining raised investment amount and handling fee funds
Pharmaceutical logistics phase II construction project 12024.5211636.41637 551,025.66
The company plans to close the raised investment project. After closing, the surplus raised funds of the raised investment project are 10.2566 million yuan (including interest income and handling charges, and the actual amount shall be subject to the balance of the special account on the day of fund transfer out), accounting for 8.53% of the net raised funds of the project.
2. Pharmaceutical wholesale business expansion project
As of November 30, 2021, the “pharmaceutical wholesale business expansion project” has been implemented, and the project has reached the expected usable state. The accumulated use of the raised funds is 39.9817 million yuan, and the progress of the use of the funds is 99.95%. At the same time, the special account for the raised funds has generated certain interest income during the storage period. Specific fund use and savings are as follows:
Unit: 10000 yuan
